Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 3/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSH | P09668 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3806162 | 1.00 | METAP2 (0.44) | METAP2CTSKRENMETAP1SLC1A3 | |
| SCHEMBL702585 | 1.00 | METAP2 (0.44) | METAP2CTSKRENMETAP1SLC1A3 | |
| SCHEMBL702586 | 1.00 | METAP2 (0.44) | METAP2CTSKRENMETAP1SLC1A3 | |
| Hydrochloric Acid SCHEMBL1067413 | 0.98 | METAP2 (0.43) | METAP2CTSKRENMETAP1SLC1A3 | |
| Hydrochloric Acid SCHEMBL30730437 | 0.98 | METAP2 (0.43) | METAP2CTSKRENMETAP1SLC1A3 | |
| Hydrochloric Acid SCHEMBL3207528 | 0.98 | METAP2 (0.43) | METAP2CTSKRENMETAP1SLC1A3 | |
| Hydrochloric Acid SCHEMBL240251 | 0.98 | METAP2 (0.43) | METAP2CTSKRENMETAP1SLC1A3 | |
| SCHEMBL23849174 | 0.98 | METAP2 (0.42) | METAP2CTSKRENMETAP1SLC1A3 | |
| SCHEMBL1067305 | 0.98 | METAP2 (0.42) | METAP2CTSKRENMETAP1SLC1A3 | |
| SCHEMBL1067894 | 0.98 | METAP2 (0.42) | METAP2CTSKRENMETAP1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122153-A1 | Protease Inhibitors as Antivirals | ACEA Therapeutics, Inc. (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025011610-A1 | AMIDE DERIVATIVE, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-16 | — | — | WO | disclosed |
| CN-118103351-A | Coronavirus inhibitors | 共晶制药公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11987554-B2 | Protease inhibitors as antivirals | VIVASOR, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| EP-4347034-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117769541-A | protease inhibitors as antiviral agents | 艾森医药有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20240034753-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2024-02-01 | — | — | US | disclosed |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11753373-B2 | Protease inhibitors as antivirals | ACEA Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-5866685-A | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0812205-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-12-17 | — | — | EP | disclosed |
| WO-1995010295-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-20 | — | — | WO | disclosed |
| US-5272268-A | Dipeptide derivatives | SHIONOGI & CO., LTD. (JP) | 1993-12-21 | — | — | US | disclosed |
| US-5223615-A | Hypotensive agents | SHIONOGI & CO., LTD. (JP) | 1993-06-29 | — | — | US | disclosed |
| US-5194608-A | Hypotensive agents; inhibits renin-angiotensin system | SHIONOGI & CO., LTD. (JP) | 1993-03-16 | — | — | US | disclosed |
| EP-0468641-A2 | Renin inhibiting dipeptide derivatives, their preparation and pharmaceutical preparations containing them | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1992-01-29 | — | — | EP | disclosed |
| US-4246424-A | IN PRESENCE OF ALKALI METAL AND POLYCYCLIC AROMATIC HYDROCARBON | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-01-20 | — | — | US | disclosed |
| US-4158016-A | CONTACTING WITH AN ALKALI METAL POLYCYCLIC AROMATIC HYDROCARBON CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1979-06-12 | — | — | US | disclosed |
| US-3970700-A | Racemization of optically active amines | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1976-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122153-A1 | Protease Inhibitors as Antivirals | ACE, ACE2, TMPRSS15 | METAP2 156/4885CTSK 86/4885REN 103/4885 |
| US-11753373-B2 | Protease inhibitors as antivirals | ACE, ACE2, TMPRSS15 | METAP2 156/4885CTSK 86/4885REN 103/4885 |
| US-11987554-B2 | Protease inhibitors as antivirals | ACE, ACE2, TMPRSS15 | METAP2 156/4885CTSK 86/4885REN 103/4885 |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | METAP2 156/4885CTSK 86/4885REN 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.